No Data
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
10x Genomics Is Maintained at Overweight by Barclays
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30
No Data
No Data